Search results
Results From The WOW.Com Content Network
In the latter two, needles are used to puncture the graft or fistula each time dialysis is performed. The type of vascular access created for patients on hemodialysis is influenced by factors such as the expected time course of a patient's kidney failure and the condition of his or her vasculature.
An arteriovenous graft serving as a fistula for hemodialysis access. A vascular bypass is often created to serve as an access point to the circulatory system for hemodialysis. Such a bypass is referred to as an arteriovenous fistula if it directly connects a vein to an artery without using synthetic material. [citation needed]
Before the Cimino fistula was invented, access was through a Scribner shunt, which consisted of a Teflon tube with a needle at each end. Between treatments, the needles were left in place and the tube allowed blood flow to reduce clotting. But Scribner shunts lasted only a few days to weeks.
An arteriovenous fistula is an abnormal connection or passageway between an artery and a vein. [1] It may be congenital , surgically created for hemodialysis treatments, or acquired due to pathologic process, such as trauma or erosion of an arterial aneurysm .
Graft infection from a Bentall procedure presents similarly to many infections after a major cardiac surgery, with indications in various degrees of severity. Symptoms can include fever, chills, loss of appetite, weight loss, malaise with clinical indications including septic emboli, abscess, left ventricular fistulae, transient ischemic attack.
Type III dural fistulas need to be treated to prevent hemorrhage. Treatment can be as simple as clipping the draining vein at the site of the dural sinus. If treatment involves embolization, it will only typically be effective if the glue traverses the actual fistula and enters, at least slightly, the draining vein. [citation needed]
The extra cost of malpractice lawsuits is a proportion of health spending in both the U.S. (1.7% in 2002) [112] and Canada (0.27% in 2001 or $237 million). In Canada the total cost of settlements, legal fees, and insurance comes to $4 per person each year, [113] but in the United States it is over $16.
The immunosuppressive agents employed in allogeneic transplants for the prevention or treatment of graft-versus-host disease further increase the risk of opportunistic infection. Immunosuppressive drugs are given for a minimum of six months after a transplantation, or much longer if required for the treatment of graft-versus-host disease.